Skip to main content

Table 1 Characteristics of randomised controlled trials included in the meta-analysis

From: Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis

Source No. of participants (Intervention) Duration treatment, wk Age, Mean Male % Time since diagnosis, yr FVC, %, mean Risk of biasa
Noble et al. 2011 [4] (Capacity 06) 171 (Pirfenidone 2403 mg/day) 72 67 72 ≤1 yr: 59% 74 Low
  173 (Placebo)       
Noble et al. 2011 [4] (Capacity 04) 174 (Pirfenidone 2403 mg/day) 72 66 71 ≤1 yr: 48% 75 Low
  174 (Placebo)       
Taniguchi et al. 2010 [5] 108 (Pirfenidone 1800 mg/day) 52 65 78 <1 yr: 37% 78 Unclear
  104 (Placebo)       
Azuma et al. 2005 [6] 73 (Pirfenidone 1800 mg/day) 39 64 90 <1 yr: 22% 80 Unclear
  36 (Placebo)       
King et al. 2014 [7] (Ascend) 278 (Pirfenidone 2403 mg/day) 52 68 78 1.7 68 Low
  277 (Placebo)       
Richeldi et al. 2011 [25] 85 (Nintedanib 300 mg/day) 52 65 75 1.2 80 Low
  85 (Placebo)       
Richeldi et al. 2014 [8] (INPULSIS-1) 309 (Nintedanib 300 mg/day) 52 67 81 1.7 80 Low
  204 (Placebo)       
Richeldi et al. 2014 [8] (INPULSIS-2) 329 (Nintedanib 300 mg/day) 52 67 78 1.6 79 Low
  219 (Placebo)       
Homma et al. 2012 [24], 38 (Inhaled NAC) 48 68 76 3 89 Unclear
  38 (Placebo)       
Raghu et al. 2012 [22], (PANTHER) 77 (NAC triple therapy) 32 68 75 1.1 71 Low
  78 (Placebo)       
IPFCRN, 2014 [23] (PANTHER) 133 (NAC) 60 68 78 1.1 73 Low
  131 (Placebo)       
  1. aRisk of selection bias.